Does LUTETIUM OXODOTREOTIDE LU-177 Cause Second primary malignancy? 23 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Second primary malignancy have been filed in association with LUTETIUM OXODOTREOTIDE LU-177 (Lutathera). This represents 0.4% of all adverse event reports for LUTETIUM OXODOTREOTIDE LU-177.
23
Reports of Second primary malignancy with LUTETIUM OXODOTREOTIDE LU-177
0.4%
of all LUTETIUM OXODOTREOTIDE LU-177 reports
4
Deaths
8
Hospitalizations
How Dangerous Is Second primary malignancy From LUTETIUM OXODOTREOTIDE LU-177?
Of the 23 reports, 4 (17.4%) resulted in death, 8 (34.8%) required hospitalization, and 4 (17.4%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUTETIUM OXODOTREOTIDE LU-177. However, 23 reports have been filed with the FAERS database.
What Other Side Effects Does LUTETIUM OXODOTREOTIDE LU-177 Cause?
Ill-defined disorder (1,538)
General physical health deterioration (906)
Death (431)
Malignant neoplasm progression (338)
Platelet count decreased (220)
Nausea (214)
Covid-19 (193)
Fatigue (185)
Diarrhoea (169)
Disease progression (169)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LUTETIUM OXODOTREOTIDE LU-177 Alternatives Have Lower Second primary malignancy Risk?
LUTETIUM OXODOTREOTIDE LU-177 vs LUTROPIN ALFA
LUTETIUM OXODOTREOTIDE LU-177 vs LYMECYCLINE
LUTETIUM OXODOTREOTIDE LU-177 vs LYRICA
LUTETIUM OXODOTREOTIDE LU-177 vs LYSERGIDE
LUTETIUM OXODOTREOTIDE LU-177 vs MABTHERA